Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.

Shi C, Xiong Z, Chittepu P, Aldrich CC, Ohlfest JR, Ferguson DM.

ACS Med Chem Lett. 2012 Jun 14;3(6):501-504.

2.

Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.

Schiaffo CE, Shi C, Xiong Z, Olin M, Ohlfest JR, Aldrich CC, Ferguson DM.

J Med Chem. 2014 Jan 23;57(2):339-47. doi: 10.1021/jm4004957. Epub 2014 Jan 10.

PMID:
24383475
3.

Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.

Loré K, Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, Perfetto S, Roederer M, Seder RA, Koup RA.

J Immunol. 2003 Oct 15;171(8):4320-8.

4.

Toll-like receptor 7 inactive ligands enhanced cytokine induction by conjugation to weak antigens.

Gao D, Diao Y, Li W, Gao N, Liu Y, Wang Z, Jiang W, Jin G.

ChemMedChem. 2015 Jun;10(6):977-80. doi: 10.1002/cmdc.201500088. Epub 2015 Apr 16.

PMID:
25882779
5.

TLR activation pathways in HIV-1-exposed seronegative individuals.

Biasin M, Piacentini L, Lo Caputo S, Naddeo V, Pierotti P, Borelli M, Trabattoni D, Mazzotta F, Shearer GM, Clerici M.

J Immunol. 2010 Mar 1;184(5):2710-7. doi: 10.4049/jimmunol.0902463. Epub 2010 Feb 1.

6.

Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists.

Huang H, Ostroff GR, Lee CK, Wang JP, Specht CA, Levitz SM.

Infect Immun. 2009 May;77(5):1774-81. doi: 10.1128/IAI.00086-09. Epub 2009 Mar 9.

7.

The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.

Vasilakos JP, Tomai MA.

Expert Rev Vaccines. 2013 Jul;12(7):809-19. doi: 10.1586/14760584.2013.811208. Review.

PMID:
23885825
8.

Whole blood stimulation with Toll-like receptor (TLR)-7/8 and TLR-9 agonists induces interleukin-12p40 expression in plasmacytoid dendritic cells in rhesus macaques but not in humans.

Koopman G, Beenhakker N, Burm S, Bouwhuis O, Bajramovic J, Sommandas V, Mudde G, Mooij P, 't Hart BA, Bogers WM.

Clin Exp Immunol. 2013 Oct;174(1):161-71. doi: 10.1111/cei.12155.

9.

IL-29 enhances Toll-like receptor-mediated IL-6 and IL-8 production by the synovial fibroblasts from rheumatoid arthritis patients.

Xu L, Feng X, Tan W, Gu W, Guo D, Zhang M, Wang F.

Arthritis Res Ther. 2013 Oct 29;15(5):R170. doi: 10.1186/ar4357.

10.

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.

Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP.

Vaccine. 2004 Apr 16;22(13-14):1799-809.

PMID:
15068864
11.

Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways.

Philbin VJ, Dowling DJ, Gallington LC, Cortés G, Tan Z, Suter EE, Chi KW, Shuckett A, Stoler-Barak L, Tomai M, Miller RL, Mansfield K, Levy O.

J Allergy Clin Immunol. 2012 Jul;130(1):195-204.e9. doi: 10.1016/j.jaci.2012.02.042. Epub 2012 Apr 21.

12.

The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.

Domingues R, de Carvalho GC, da Silva Oliveira LM, Futata Taniguchi E, Zimbres JM, Aoki V, da Silva Duarte AJ, Sato MN.

Br J Dermatol. 2015 Jan;172(1):48-55. doi: 10.1111/bjd.13214. Epub 2014 Nov 20.

PMID:
24976336
13.

The antitumoral mode of action of imiquimod and other imidazoquinolines.

Schön M, Schön MP.

Curr Med Chem. 2007;14(6):681-7. Review.

PMID:
17346155
14.

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.

Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP.

Cell Immunol. 2002 Jul-Aug;218(1-2):74-86.

PMID:
12470615
15.

Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines.

Mitchell D, Yong M, Raju J, Willemsen N, Black M, Trent A, Tirrell M, Olive C.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:85-93. Epub 2011 Jan 1.

PMID:
21245658
16.

Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.

Huen AO, Rook AH.

Curr Opin Oncol. 2014 Mar;26(2):237-44. doi: 10.1097/CCO.0000000000000048. Review.

PMID:
24441505
17.

The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells.

Burns RP Jr, Ferbel B, Tomai M, Miller R, Gaspari AA.

Clin Immunol. 2000 Jan;94(1):13-23.

PMID:
10607486
18.

The combination of early and rapid type I IFN, IL-1α, and IL-1β production are essential mediators of RNA-like adjuvant driven CD4+ Th1 responses.

Madera RF, Wang JP, Libraty DH.

PLoS One. 2011;6(12):e29412. doi: 10.1371/journal.pone.0029412. Epub 2011 Dec 19.

19.

Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.

Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu H, Scherr DS.

J Urol. 2007 Jun;177(6):2347-51.

PMID:
17509356
20.

Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses.

Ghosh TK, Mickelson DJ, Fink J, Solberg JC, Inglefield JR, Hook D, Gupta SK, Gibson S, Alkan SS.

Cell Immunol. 2006 Sep;243(1):48-57. Epub 2007 Jan 23.

PMID:
17250816

Supplemental Content

Support Center